New cervical cancer treatment strategy could improve survival

A novel treatment regimen may be effective in patients with cervical cancer.

Standard treatment in this patient population typically involves chemoradiotherapy; however, many patients may relapse following treatment.

In a phase III INTERLACE trial published in The Lancet, researchers randomly assigned 500 patients aged 18 years and older with locally advanced cervical cancer to receive either induction chemotherapy followed by standard cisplatin-based chemoradiotherapy or standard cisplatin-based chemoradiotherapy alone.

After a median follow-up of 67 months, the patients who received the induction chemotherapy followed by standard chemoradiotherapy experienced a five-year progression-free survival rate of 72% vs 64% among those who received standard chemoradiotherapy alone. The overall survival rate was 80% in the induction chemotherapy followed by standard chemoradiotherapy group compared with 72% in the standard chemoradiotherapy alone group.

The findings indicated that induction chemotherapy followed by standard chemoradiotherapy may significantly improve the survival outcomes in patients with cervical cancer.

Read more: The Lancet

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.